Luteolin is a naturally occurring flavonoid—a class of plant compounds with antioxidant and anti-inflammatory properties—found abundantly in vegetables, fruits, and herbs such as celery, parsley, chamomile, and oregano. As a dietary supplement, luteolin has gained attention in both research communities and consumer health circles for its potential neuroprotective effects, immune-modulating capacity, and anti-inflammatory action.
Unlike many supplements marketed with minimal scientific backing, luteolin is supported by a growing body of mechanistic research demonstrating how it works at the cellular level. However, it's important to understand the distinction between compelling laboratory evidence and proven human efficacy—a distinction that shapes how we should interpret current claims about its benefits.
This article examines what the evidence actually shows about luteolin's effects on various aspects of health, from cognitive function to athletic performance, while clarifying which claims rest on solid human data and which remain largely theoretical.
Luteolin exerts its biological effects through multiple pathways that work synergistically:
The primary anti-inflammatory mechanism involves inhibition of NF-κB activation, a master regulatory protein that controls the expression of pro-inflammatory genes. By blocking NF-κB, luteolin suppresses the release of key inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β).
Additionally, luteolin suppresses mast cell degranulation—the release of inflammatory molecules from immune cells—further reducing systemic inflammation. This dual action on both NF-κB signaling and immune cell activity makes it a multi-target anti-inflammatory agent.
Luteolin directly scavenges reactive oxygen species (ROS)—unstable molecules that damage cells—and chelates metal ions that can generate oxidative stress. This antioxidant capacity operates independently of its anti-inflammatory effects, providing complementary cellular protection.
Luteolin acts as a potent inhibitor of phosphodiesterase (PDE) enzymes, which normally break down intracellular signaling molecules called cAMP. By inhibiting PDE, luteolin raises intracellular cAMP levels, a messenger molecule implicated in neuroprotection, energy metabolism, and anti-inflammatory responses.
Through modulation of the PI3K/Akt/mTOR pathway and activation of AMPK (an energy-sensing enzyme), luteolin influences cellular metabolism and protein synthesis signaling. These pathways are central to aging, metabolic health, and mitochondrial function.
Evidence Tier: 2 — Luteolin shows neuroprotective promise in animal models and cell cultures, but rigorous human evidence remains absent.
In rat models of cognitive impairment, luteolin cotreatment (20-40 mg/kg) significantly reversed behavioral deficits and neurodegeneration in the cortex and hippocampus. In a separate study using D-galactose-induced brain aging rats, luteolin effectively reversed cognitive impairment, corrected cholinergic abnormalities, and upregulated SIRT1 mRNA expression in the hippocampus—a gene associated with longevity pathways.
However, no rigorous randomized controlled trials in humans have directly tested whether luteolin improves cognitive outcomes in healthy individuals or those with cognitive decline. The mechanistic promise is clear, but clinical translation requires human evidence.
Evidence Tier: 2 — Luteolin shows theoretical promise through pathways implicated in mood regulation, but zero human randomized controlled trials exist.
Luteolin has been identified in mechanistic analyses as a compound that modulates BDNF (brain-derived neurotrophic factor), AMPK, and NF-κB pathways relevant to mood and stress comorbidities. In animal neuropathy models, luteolin combined with stem cells reduced oxidative stress and inhibited reactive astrocytes—cells that can amplify neuroinflammation.
Despite these mechanisms, direct clinical evidence for luteolin's effects on human mood or stress remains absent. Current evidence is observational at best.
Evidence Tier: 1 — No studies directly test luteolin's effects on sleep.
Luteolin is one of approximately 25 flavonoids found in Ziziphora clinopodioides, a traditional medicine historically used for insomnia. While this plant and its flavonoid constituents show neuroprotective effects in animal models through anti-apoptotic, anti-inflammatory, and antioxidant pathways, no research isolates luteolin's specific contribution to sleep improvement.
Evidence Tier: 2 — Luteolin shows consistent anti-aging effects in animal models, with one notable human observational study.
In a large cross-sectional analysis of 10,789 US adults, higher dietary luteolin intake was associated with a 9.6% reduction in phenotypic age acceleration per 2.7-fold increase in intake. The odds ratio for age acceleration in the highest dietary intake group (Q4) versus the lowest (Q1) was 0.736, suggesting a meaningful protective association.
However, this observational data cannot prove causation. No randomized controlled trials in humans directly test whether luteolin supplementation extends lifespan or reduces biological aging markers.
Evidence Tier: 2 — Luteolin demonstrates consistent anti-inflammatory effects in animal and cell studies, but human clinical efficacy remains unproven.
A meta-analysis of 33 studies, predominantly preclinical, showed that luteolin reduced expression of pro-inflammatory cytokine genes through inhibition of toll-like receptor and NF-κB pathways, and suppressed both NLRP3 inflammasome and nuclear factor-kappa signaling. In human observational work, luteolin combined with stem cell therapy reduced sensory deficits and oxidative stress markers in neuropathic pain models, with documented inhibition of reactive astrocytes.
No randomized controlled trials in humans have demonstrated clinical benefits of luteolin supplementation for reducing inflammation.
Evidence Tier: 2 — Luteolin shows mechanistic immune effects in laboratory studies, but human evidence for functional immune improvement is absent.
In a systematic review of 33 sepsis studies (mostly animal models), luteolin reduced NF-κB, NLRP3, and pro-inflammatory cytokine gene expression, and reduced macrophage and neutrophil overactivity. In immune cell models, luteolin promotes regulatory T cell (Treg) differentiation, suppresses Th17 responses, and shifts macrophage polarization toward the M2 anti-inflammatory phenotype through STAT3/STAT6 and PPARγ pathways.
Yet no human randomized controlled trials demonstrate that luteolin supplementation improves actual immune function or clinical infection outcomes in healthy or diseased populations.
Evidence Tier: 2 — Luteolin shows consistent cartilage-protective effects in animal models and cell culture, but human clinical trials are absent.
In rat chondrocytes (cartilage cells), luteolin at 25-100 μM dose-dependently reduced interleukin-1 beta-induced nitric oxide, prostaglandin E2 (PGE2), TNF-α, and matrix metalloproteinases (MMPs)—enzymes that degrade collagen. In a rat osteoarthritis model, luteolin at 10 mg/kg/day reversed collagen type II degradation.
In guinea pig osteoarthritis cartilage, luteolin downregulated JNK and p38 MAPK expression and reduced nitric oxide, TNF-α, and IL-6 levels, protecting cartilage cells from degeneration. However, no human clinical trials have tested whether luteolin supplementation improves joint pain, function, or cartilage health in osteoarthritis patients.
Evidence Tier: 3 — Multiple human observational studies suggest cardiovascular benefit, supported by consistent animal research.
In a prospective cohort study of 2,393 chronic kidney disease patients followed for a median of 93 months, each per-unit increase in dietary luteolin intake reduced all-cause mortality by 27% (P<0.001) and cardiovascular mortality by 34% (P=0.01), with a clear dose-response relationship. This is the most robust human evidence available for any luteolin outcome.
In animal models, luteolin protects the heart during ischemia-reperfusion injury in diabetic rats, reducing myocardial infarct size, decreasing arrhythmia incidence, enhancing left ventricular ejection fraction, and reducing cardiomyocyte apoptosis compared to untreated injury.
Despite these promising associations, no human randomized controlled trials exist testing luteolin supplementation for cardiovascular outcomes.
Evidence Tier: 2 — Luteolin demonstrates hepatoprotective effects in multiple animal models, but no human trials exist.
In rats with tamoxifen-induced fatty liver, luteolin at 20-40 mg/kg decreased serum aminotransferases and attenuated hepatic steatosis. In mice with LPS/D-galactose-induced acute liver failure, luteolin reduced serum ALT and AST levels, suppressed pro-inflammatory cytokines, increased antioxidant enzyme activity (catalase and superoxide dismutase), and suppressed oxidative stress markers.
These findings are consistent but remain unproven in human patients.
Evidence Tier: 2 — One small human RCT shows benefit for cognitive fatigue in long-COVID patients; broader energy claims lack human evidence.
In a 39-patient randomized controlled trial of people with long-COVID, eight weeks of PEA-luteolin supplementation (70 mg luteolin component) restored GABA-B activity, increased long-interval intracortical inhibition, and enhanced long-term potentiation-like cortical plasticity compared to placebo—suggesting improved central nervous system function and energy.
In rat cardiomyocytes, luteoloside pretreatment (20 μM) increased cell viability, restored intracellular ATP levels, stabilized mitochondrial membrane potential, and enhanced autophagy through AMPK-mTOR/ULK1 pathway activation. However, efficacy for general energy production in healthy humans remains unproven.
Evidence Tier: 2 — One human RCT shows improved sprint performance; broader athletic benefit claims remain preliminary.
In a 12-person randomized controlled trial, acute and 15-day supplementation with luteolin plus mangiferin enhanced sprint exercise performance and improved muscle oxygen extraction compared to placebo, with similar benefits at both low (50 mg/100 mg) and high (100 mg/420 mg) doses. Luteolin increased muscle oxygen extraction during post-exercise ischemia and improved sprint performance after ischemia-reperfusion, likely through increased glycolytic energy production (reflected in higher blood lactate).
Two animal studies support anti-fatigue effects, but human evidence for broader athletic performance benefits remains limited to this single small trial.
Evidence Tier: 2 — Limited human evidence; promising animal models suggest potential benefit.
In a human randomized controlled trial (n=12) for post-COVID olfactory dysfunction, patients receiving PEA-luteolin supplement combined with olfactory rehabilitation showed improved Sniffin' Sticks scores at 30 days compared to rehabilitation alone.
In a mouse model of traumatic brain injury, co-ultramicronized PEA-luteolin treatment increased neurogenesis at 72 hours and 7 days post-injury, upregulated neurotrophic factors, and showed improvements in memory recall on behavioral testing. These findings suggest neuroprotective potential, but broader injury recovery efficacy in humans requires additional research.
Evidence Tier: 2 — Promising mechanistic data in animals; no human randomized controlled trials demonstrate weight loss efficacy.
In mice with injectable luteolin-loaded hydrogel, luteolin decreased white adipose tissue mass, promoted white adipocyte browning (conversion to brown fat), and increased energy expenditure. Luteolin activates AMPK and modulates NF-κB inflammatory pathways implicated in obesity and metabolic dysfunction.
However, no human randomized controlled trials have demonstrated efficacy for weight loss or fat reduction. The animal evidence is compelling but insufficient for clinical claims.
Evidence Tier: 2 — Animal studies show promising effects on hair growth and skin health; no human clinical trials exist.
Topical luteolin combined with simvastatin in mice increased hair count, hair follicle diameter, and tissue VEGF and KGF levels versus control over three weeks. In human keratinocytes (skin cells), luteolin at 10-100 μM suppressed TNF-induced interleukin-6, interleukin-8, and VEGF release in a dose-dependent manner and reduced NF-κB phosphorylation—mechanisms relevant to skin inflammation and aging.
Despite these mechanisms, no human randomized controlled trials have tested luteolin for skin or hair health outcomes.
Evidence Tier: 2 — Animal studies demonstrate intestinal barrier protection; no human trials exist.
In piglets fed soybean meal, luteolin supplementation significantly increased average daily gain, reduced diarrhea incidence, increased intestinal villi height and villi-to-crypt ratio, and reduced serum diamine oxidase (indicating improved intestinal barrier function). In chickens exposed to cadmium, luteolin maintained liver and intestinal morphology, reduced oxidative stress markers, restored intestinal barrier function, and normalized gut microbiota composition.
These findings suggest therapeutic potential, but human evidence remains absent.
Evidence Tier: 1 — No evidence for muscle growth in humans or animals specifically measuring skeletal muscle.
Luteolin has not been studied for muscle growth. One in-vitro cell study showed luteolin used with rosiglitazone decreased white adipose tissue mass and lipid storage, with no measurement of skeletal muscle effects. Critically, luteolin inhibits the PI3K/AKT pathway in some contexts—a pathway essential for muscle protein synthesis—raising questions about potential negative effects on anabolic signaling.
Evidence Tier: 1 — No human evidence; preliminary animal data only.
Luteolin has not been proven effective for sexual health in humans. It was identified as a candidate therapeutic for further research in provoked vestibulodynia (vulvodynia) based on expert consensus, ranked 4th among 15 proposed treatments at a therapeutic research summit—but this represents expert opinion rather than clinical evidence.
In zebrafish PCOS models, luteolin protected ovarian cells from BPA-induced damage, increased antioxidant enzyme activity, and induced follicular maturation. These animal findings suggest a research direction but provide no evidence of human sexual or reproductive benefit.
Evidence Tier: 2 — Plausible mechanisms in animal and cell models; no human evidence for hormonal outcomes.
In zebrafish PCOS models, luteolin alleviated total SOD levels in the ovary, induced follicular maturation, and altered key genes in ovarian proliferation and the pro-inflammatory cytokine TNF-α. In Chinese hamster ovary cells, luteolin protected against BPA-induced reactive oxygen species, cellular damage, and negative mitochondrial membrane potential.
The only hormonal-specific human data comes from mechanistic studies in post-COVID patients, not reproductive or endocrine outcomes. Efficacy for human hormonal balance remains unproven.
Standard oral dosing ranges from 100-600 mg once to twice daily. Most human studies use dosing at the lower to mid-range of this spectrum (50-100 mg in combination supplements; up to 600 mg in single-ingredient formulations).
The small human athletic performance study used 50-100 mg luteolin in combination with mangiferin. The long-COVID energy study used a PEA-luteolin combination providing 70 mg of luteolin. Olfactory dysfunction recovery studies used similar PEA-luteolin combinations.
Higher doses (400-600 mg) are available in single-ingredient supplements but lack human efficacy data. Standard dosing recommendations suggest starting at 100-200 mg daily to assess tolerance, with increases to 300-400 mg daily if needed.
Bioavailability varies significantly by formulation; liposomal and micronized versions show superior absorption compared to standard powders. Consistency matters—daily supplementation likely produces better results than sporadic use, though no formal dose-frequency studies exist.
Gastrointestinal discomfort is the most frequently reported adverse effect, particularly at higher doses (300-600 mg). Symptoms include nausea and bloating, typically mild and self-limiting.
Diarrhea or loose stools occur more frequently with standard non-liposomal formulations, likely due to poor absorption and osmotic effects in the intestine. Liposomal or micronized preparations may reduce this risk.
Mild headache during initial use has been documented and often resolves within several days as